Biomica, a subsidiary of Evogene, and Lishan Biotech have agreed to a worldwide, exclusive licensing deal for a microbiome-based therapeutic. BMC128, designated as LS-LBP-002 by Lishan, is a first-in-class therapeutic developed by Biomica, designed to enhance anti-tumor immune activity. Currently, BMC128 is completing a Phase I clinical trial in renal cell carcinoma and non-small cell lung cancer. Early clinical results have been promising, with an excellent safety and tolerability profile as...